钠-葡萄糖协同转运蛋白2抑制剂与痴呆发生时间的关联:一项基于人群的队列研究
这项基于人群的回顾性队列研究纳入106,903例≥66岁、2016年7月1日至2021年3月31日期间新使用SGLT2抑制剂或DPP-4抑制剂的安大略居民,采用倾向评分加权Cox模型分析。平均随访2.80年,SGLT2抑制剂组较DPP-4抑制剂组痴呆风险更低(aHR 0.80,95%CI 0.71-0.89),其中达格列净aHR最低(0.67),恩格列净aHR 0.78,卡格列净无关联(aHR 0.96)。作者结论为SGLT2抑制剂与较低痴呆风险相关,需随机对照试验验证。
要点
- SGLT2抑制剂较DPP-4抑制剂与更低痴呆风险相关(aHR 0.80,95%CI 0.71-0.89)。
- 达格列净aHR 0.67(95%CI 0.53-0.84),恩格列净aHR 0.78(95%CI 0.69-0.89)。
- 卡格列净与痴呆风险无关联(aHR 0.96,95%CI 0.80-1.16)。
核心结论
- 在老年2型糖尿病患者中,SGLT2抑制剂与较低痴呆风险相关。
- 作者结论指出需随机对照试验验证。
研究设计与样本
- 基于人群的回顾性队列研究,纳入安大略居民 aged ≥66 years 新使用SGLT2抑制剂或DPP-4抑制剂者,入组时间为2016年7月1日至2021年3月31日。
- 共纳入106,903例个体,采用倾向评分加权Cox比例风险模型估计调整风险比(aHR)及置信区间。
- 主要分析采用意向治疗暴露定义,并进行按实际治疗分析;观察窗从队列 entry 后1年滞后时间开始。
主要发现
- 平均随访2.80年,SGLT2抑制剂组痴呆发生率为14.2/1,000人年,较DPP-4抑制剂组风险更低(aHR 0.80,95%CI 0.71-0.89)。
- 达格列净aHR 0.67(95%CI 0.53-0.84),恩格列净aHR 0.78(95%CI 0.69-0.89),卡格列净aHR 0.96(95%CI 0.80-1.16)。
- 按实际治疗分析中关联幅度大于意向治疗分析(aHR 0.66,95%CI 0.57-0.76)。
关键数值与推荐
- SGLT2抑制剂较DPP-4抑制剂:aHR 0.80(95%CI 0.71-0.89)。
- 达格列净:aHR 0.67(95%CI 0.53-0.84)。
- 恩格列净:aHR 0.78(95%CI 0.69-0.89)。
- 卡格列净:aHR 0.96(95%CI 0.80-1.16)。
- 按实际治疗分析:aHR 0.66(95%CI 0.57-0.76)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者结论指出需随机对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type 2 diabetes (T2D) increases dementia risk, but clear evidence to recommend interventions that can mitigate that risk remains lacking. This population-based retrospective cohort study aimed to determine whether new use of sodium-glucose cotransporter 2 (SGLT2) inhibitors compared with dipeptidyl peptidase 4 (DPP-4) inhibitors was associated with lower dementia risk. RESEARCH DESIGN AND METHODS: Ontario residents aged ≥66 years who were new users of an SGLT2 inhibitor or a DPP-4 inhibitor from 1 July 2016 to 31 March 2021 entered the cohort. Incident dementia was identified using a validated algorithm for Alzheimer's disease and related dementias. Propensity score-weighted Cox proportional hazards models were used to obtain adjusted hazard ratios (aHR) and CIs for time to incident dementia. To address reverse causality and disease latency, the observation window started at 1-year lag time from cohort entry. The primary analysis followed intention-to-treat exposure definition, and a secondary as-treated analysis was performed. RESULTS: Among 106,903 individuals, SGLT2 inhibitors compared with DPP-4 inhibitors were associated with lower risk of dementia (14.2/1,000 person-years; aHR 0.80 [95% CI 0.71-0.89]) over a mean follow-up of 2.80 years from cohort entry. When stratified by different SGLT2 inhibitors, dapagliflozin exhibited the lowest risk (aHR 0.67 [95% CI 0.53-0.84]), followed by empagliflozin (aHR 0.78 [95% CI 0.69-0.89]), whereas canagliflozin showed no association (aHR 0.96 [95% CI 0.80-1.16]). The as-treated analysis observed a larger association (aHR 0.66 [95% CI 0.57-0.76]) than the intention-to-treat analysis. CONCLUSIONS: SGLT2 inhibitors showed an association with lower dementia risk in older people with T2D. Randomized controlled trials are warranted.
引用
- Wu CY, Iskander C, Wang C, et al. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study. Diabetes Care. 2023. PMID: 36508692. doi:10.2337/dc22-1705
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。